<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00146562</url>
  </required_header>
  <id_info>
    <org_study_id>03-154</org_study_id>
    <nct_id>NCT00146562</nct_id>
  </id_info>
  <brief_title>Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer</brief_title>
  <official_title>A Phase II Study of Pegfilgrastim (Neulasta) and Darbepoetin Alfa (Aranesp) in Support of Dose-Dense Adjuvant Chemotherapy for Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Harold J. Burstein, MD, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lowell General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>North Shore Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <brief_summary>
    <textblock>
      The main purpose of this study is to see if pegfilgrastim (Neulasta) is safe and useful in&#xD;
      supporting people through dose-dense chemotherapy, and to see if a long-acting red blood cell&#xD;
      growth factor, darbepoetin alfa(Aranesp) can reduce the need for blood transfusion in&#xD;
      chemotherapy recipients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Patients will receive chemotherapy every 2 weeks for up to 8 cycles (spread out of&#xD;
           approximately 16 weeks, total) of treatment. On the day of chemotherapy treatment&#xD;
           patients may receive an injection of darbepoetin alfa in addition to chemotherapy if&#xD;
           their red blood cell count is below normal levels.&#xD;
&#xD;
        -  On the day after chemotherapy treatment, patients will receive an injection of&#xD;
           pegfilgrastim. There is one pegfilgrastim shot given per treatment cycle, for a total of&#xD;
           8 injections. Once the patient has finished chemotherapy and the last of the&#xD;
           pegfilgrastim shots, their participation in this trial will be complete.&#xD;
&#xD;
        -  While on this study the following procedures will be performed: a physical exam will be&#xD;
           done every 2 weeks, vital signs will be done every 2 weeks, and blood tests every 2&#xD;
           weeks.&#xD;
&#xD;
        -  This study also involves a Quality of Life Questionnaire done at the beginning of study&#xD;
           treatment, at 2 months, 4 months, 6 months, and 1 year after starting the study&#xD;
           treatment.&#xD;
&#xD;
        -  Patients will remain on this study unless they experience unacceptable side effects from&#xD;
           any of the treatment drugs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the rate of febrile neutropenia in women treated with dose-dense adjuvant chemotherapy receiving pegfilgrastim every 2 weeks.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the rate of RBC transfusion among patients treated with dose-dense adjuvant chemotherapy receiving darbepoetin every 2 weeks.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">109</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Stage I Breast Cancer</condition>
  <condition>Stage II Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darbepoetin Alfa</intervention_name>
    <description>Given day before chemotherapy of red blood cell count is below normal</description>
    <other_name>Aranesp</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegfilgrastim</intervention_name>
    <description>Given as an injection the day before chemotherapy for a total of 8 injections</description>
    <other_name>Neulasta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>As part of standard adjuvant chemotherapy: Given every two weeks for 8 cycles</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>As part of standard adjuvant chemotherapy: Given every two weeks for 8 cycles</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>As part of standard adjuvant chemotherapy: Given every two weeks for 8 cycles</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed breast cancer clinical stage I, II or III&#xD;
             disease. Patients must be deemed of sufficient risk for tumor or recurrence&#xD;
&#xD;
          -  Patients may receive the defined adjuvant chemotherapy treatment either following&#xD;
             definitive breast surgery or prior to definitive breast surgery&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  ECOG performance status 0 or 1&#xD;
&#xD;
          -  ANC &gt; 1,500/uL&#xD;
&#xD;
          -  Hemoglobin &gt; 9 g/dL&#xD;
&#xD;
          -  Platelets &gt; 100,000/ul&#xD;
&#xD;
          -  Total bilirubin less than or equal to ULN&#xD;
&#xD;
          -  AST/ALT &lt; 1.5 x ULN&#xD;
&#xD;
          -  Creatinine within normal institutional limits&#xD;
&#xD;
          -  PT/PTT &lt; institutional upper limit of normal&#xD;
&#xD;
          -  LVEF &gt; 50%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous cytotoxic chemotherapy or therapeutic radiation therapy&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Receiving any other investigational agents&#xD;
&#xD;
          -  Stage IV breast cancer&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to pegfilgrastim or darbepoetin&#xD;
&#xD;
          -  Previous exposure to G-CSF or pegfilgrastim or to recombinant erythropoetin-related&#xD;
             growth factors.&#xD;
&#xD;
          -  On antibiotics within 72 hours of registration&#xD;
&#xD;
          -  Patients with immune deficiency who are at increased risk of lethal infections when&#xD;
             treated with marrow-suppressive therapy, or HIV-positive patients receiving&#xD;
             anti-retroviral therapy&#xD;
&#xD;
          -  Sickle cell disease&#xD;
&#xD;
          -  Known positive antibody response to any erythropoietic agent&#xD;
&#xD;
          -  Known hematologic diseases&#xD;
&#xD;
          -  Known history of hyperviscosity syndrome&#xD;
&#xD;
          -  Patients on lithium&#xD;
&#xD;
          -  RBC transfusion within past 4 weeks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harold Burstein, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faulkner Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lowell General Hospital</name>
      <address>
        <city>Lowell</city>
        <state>Massachusetts</state>
        <zip>01854</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore Cancer Center</name>
      <address>
        <city>Peabody</city>
        <state>Massachusetts</state>
        <zip>01960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>September 2, 2005</study_first_submitted>
  <study_first_submitted_qc>September 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2005</study_first_posted>
  <last_update_submitted>February 15, 2013</last_update_submitted>
  <last_update_submitted_qc>February 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Harold J. Burstein, MD, PhD</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>adjuvant chemotherapy</keyword>
  <keyword>G-CSF</keyword>
  <keyword>pegfilgrastim</keyword>
  <keyword>darbepoetin alfa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Darbepoetin alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

